Filing Details

Accession Number:
0001209191-19-062325
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-12-31 18:26:42
Reporting Period:
2019-12-27
Accepted Time:
2019-12-31 18:26:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1645460 Cue Biopharma Inc. CUE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
897744 A Christopher Marlett 2425 Cedar Springs Road
Dallas TX 75201
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2019-12-27 9,000 $17.24 775,203 No 4 S Indirect See footnote
Common Stock Disposition 2019-12-31 6,700 $15.77 768,503 No 4 S Indirect See footnote
Common Stock Disposition 2019-12-31 9,000 $15.71 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
No 4 S Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.01 to $17.56, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  2. Held by the Christopher A. Marlett Living Trust, of which the reporting person is sole trustee.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.60 to $16.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.60 to $15.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.